Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019

Lina van der Straten(Erasmus MC), Avinash G. Dinmohamed(Netherlands Comprehensive Cancer Organisation), Eduardus F. M. Posthuma(Leiden University Medical Center), Manette A. W. Dinnessen(Netherlands Comprehensive Cancer Organisation), Otto Visser(Netherlands Comprehensive Cancer Organisation), Arnon P. Kater(Amsterdam University Medical Centers), Mark‐David Levin(Albert Schweitzer Hospital), Anton W. Langerak(Erasmus MC), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
Blood Cancer Journal
January 13, 2023
10.1038/s41408-023-00784-z
Cited by 36

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
|Journal of Clinical Oncology|2010|478